Sino Biopharmaceutical Limited
SBHMYOTCHealthcare● Active
$12.98
$-1.96(-13.12%)
Market Cap$11.6B
P/E Ratio—
52W High$20.16
52W Low$9.48
Sino Biopharmaceutical Limited (SBHMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SBHMY · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 15, 2025EPS Actual
$0.26
Revenue
$1.23B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 15, 2025
After Market Close
SBHMY reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2026 | Mar 18, 2026 | — | — | — | — | — | — |
| — Q3 FY2025 | Aug 15, 2025 | — | $0.26 | — | $1.23B | — | — |
| ◌ Q2 FY2025 | Jun 5, 2025 | — | — | — | — | — | — |
| — Q1 FY2025 | Mar 26, 2025 | — | $0.00 | — | $0.89B | — | — |
| — Q1 FY2025 | Mar 20, 2025 | — | $0.00 | — | $0.93B | — | — |
| — Q3 FY2024 | Aug 13, 2024 | — | $0.01 | — | $1.09B | — | — |
| — Q2 FY2024 | Apr 8, 2024 | — | $0.01 | — | $1.10B | — | — |
| — Q1 FY2024 | Mar 28, 2024 | — | $0.00 | — | $3.70B | — | — |
Q1 FY2026
Mar 18, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 15, 2025
EPS Actual
$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$1.23B
Q2 FY2025
Jun 5, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 26, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.89B
Q1 FY2025
Mar 20, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.93B
Q3 FY2024
Aug 13, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.09B
Q2 FY2024
Apr 8, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.10B
Q1 FY2024
Mar 28, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$3.70B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Aug 15, 2025 | — | $19.50 | $19.50 | +0.00% |
| — Q1 FY2025 | Mar 26, 2025 | — | $8.95 | $8.95 | +0.00% |
| — Q1 FY2025 | Mar 20, 2025 | — | $8.06 | $8.06 | +0.00% |
| — Q3 FY2024 | Aug 13, 2024 | — | $7.25 | $7.25 | +0.00% |
| — Q2 FY2024 | Apr 8, 2024 | — | $7.41 | $7.20 | -2.83% |
| — Q1 FY2024 | Mar 28, 2024 | — | $8.20 | $8.20 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $9.63 | $9.63 | +0.00% |
| — Q1 FY2023 | Mar 31, 2023 | — | $10.82 | $11.18 | +3.33% |
Q3 FY2025+0.00%
Report Date
Aug 15, 2025
EPS Beat/Miss
—
Price Before
$19.50
Price After
$19.50
Q1 FY2025+0.00%
Report Date
Mar 26, 2025
EPS Beat/Miss
—
Price Before
$8.95
Price After
$8.95
Q1 FY2025+0.00%
Report Date
Mar 20, 2025
EPS Beat/Miss
—
Price Before
$8.06
Price After
$8.06
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$7.25
Price After
$7.25
Q2 FY2024-2.83%
Report Date
Apr 8, 2024
EPS Beat/Miss
—
Price Before
$7.41
Price After
$7.20
Q1 FY2024+0.00%
Report Date
Mar 28, 2024
EPS Beat/Miss
—
Price Before
$8.20
Price After
$8.20
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$9.63
Price After
$9.63
Q1 FY2023+3.33%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$10.82
Price After
$11.18
Beat Rate0 / 8 quarters
Largest Move+3.33% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SBHMY ends December
Sino Biopharmaceutical Limited (SBHMY) most recently reported earnings on August 15, 2025 for Q3 FY2025, posting EPS of $0.26 (in line with the analyst consensus of —). The next SBHMY earnings date is expected around September 1, 2026.
Each quarter, investors track SBHMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SBHMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SBHMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SBHMY earnings · 4 questionsSino Biopharmaceutical Limited's next earnings report is expected around September 1, 2026. SBHMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SBHMY historically reports after market close (AMC).
SBHMY earnings datewhen is SBHMY earningsSBHMY next earnings datewhen does SBHMY report earningsSBHMY earnings calendar
▸ Source: FMP · Sino Biopharmaceutical Limited SEC filings · US GAAP · Sino Biopharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026